Personalised portfoliosIslamic investingPricing and feesAbout usHelp centre
Healthcare

Healthcare

Companies advancing medical treatments and health services

0 items
Valuation
Price
TXG
10x Genomics, Inc. Class A Common Stock
TXG
44
$2.22B
-
$17.71
2.06%
FDMT
4D Molecular Therapeutics, Inc. Common Stock
FDMT
33
$436.63M
-
$8.80
2.86%
SXTP
60 Degrees Pharmaceuticals, Inc. Common Stock
SXTP
61
$5.24M
-
$1.85
-12.74%
ETNB
89bio, Inc. Common Stock
ETNB
50
$2.20B
-
$14.95
0.10%
ABBV
ABBVIE INC.
ABBV
22
$368.38B
0.83%
$208.49
0.07%
ABVC
ABVC BioPharma, Inc. Common Stock
ABVC
11
$31.04M
-
$1.29
6.15%
ACIU
AC Immune SA Common Stock
ACIU
22
$384.33M
-
$2.91
-5.83%
ACAD
ACADIA Pharmaceuticals Inc. Common Stock
ACAD
72
$3.46B
-
$20.51
0.94%
ADCT
ADC Therapeutics SA
ADCT
27
$509.45M
-
$4.00
-0.12%
ADMA
ADMA Biologics Inc Common Stock
ADMA
61
$3.54B
-
$14.80
-0.47%
AIM
AIM ImmunoTech Inc.
AIM
11
$4.30M
-
$0.92
-9.34%
ALTS
ALT5 Sigma Corporation Common Stock
ALTS
50
$173.08M
-
$1.43
4.74%
ALXO
ALX Oncology Holdings Inc. Common Stock
ALXO
33
$282.96M
-
$2.11
-1.86%
AMN
AMN Healthcare Services
AMN
38
$692.83M
-
$18.27
1.90%
ANTX
AN2 Therapeutics, Inc. Common Stock
ANTX
44
$126.60M
-
$4.00
-13.42%
ANIP
ANI Pharmaceuticals, Inc.
ANIP
61
$1.66B
-
$75.09
1.25%
SPRY
ARS Pharmaceuticals, Inc. Common Stock
SPRY
33
$824.17M
-
$8.21
-1.08%
AARD
Aardvark Therapeutics, Inc. Common Stock
AARD
44
$106.25M
-
$4.88
0.20%
ABCL
AbCellera Biologics Inc. Common Shares
ABCL
33
$1.07B
-
$3.47
-1.28%
ABT
Abbott Laboratories
ABT
55
$188.52B
0.58%
$108.18
-0.28%
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

Have any questions or just want to keep in touch?

Follow us on LinkedIn

Chat on WhatsApp

[email protected]

*T&Cs apply

Fees SchedulePrivacy & Cookies PolicyTerms & Conditions

Ramadan offerings are subject to change. Ramadan offerings are only for new CUSP Wealth users who were onboarded between February 18, 2026 - March 20, 2026 and have used the Personalised Portfolio features within the same period. CUSP Wealth has the full discretion to approve or deny the Ramadan offerings to any eligible users. Ramadan offerings are subject to T&Cs and eligibility criteria.

Cusp Wealth is a DFSA-regulated company with a Category 4 license to serve retail clients under license number 10863 and reference number F011420. We are authorised to advise on financial products and arrange deals in investments. Any information presented here is of a general nature and does not take into account your personal circumstances or financial objectives. All materials used in these communications are for marketing purposes of the Cusp Wealth Application; none are meant to offer to sell, a solicitation of an offer to buy, or a recommendation of any security or other financial instrument. They are not intended to provide investment, other financial, legal, tax, or other advice.Investments involve market volatility, possible capital loss, liquidity limits, and regulatory changes. Past performance of financial products is not a reliable indicator of future results. The value of investments can go down as well as up, and you may lose all or part of your capital. No content from Cusp Wealth should be understood as guaranteeing returns, offering risk-free investments, or promising wealth outcomes. This material is intended for DFSA-defined Retail and/or Professional Clients. If you are unsure of your classification or eligibility, please contact us at support@сuspwealth.com.

For interested persons, certain products and services are structured according to Islamic principles and approved under our DFSA-issued Islamic Endorsement. For more details, please refer to our full disclosure at https://cuspwealth.com/terms-and-conditions.